PROGYNY INC (PGNY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PGNY • US74340E1038

22.77 USD
-0.47 (-2.02%)
At close: Feb 4, 2026
22.51 USD
-0.26 (-1.14%)
After Hours: 2/4/2026, 8:00:01 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to PGNY. PGNY was compared to 102 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making PGNY a very profitable company, without any liquidiy or solvency issues. PGNY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make PGNY a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PGNY was profitable.
  • PGNY had a positive operating cash flow in the past year.
  • Each year in the past 5 years PGNY has been profitable.
  • PGNY had a positive operating cash flow in each of the past 5 years.
PGNY Yearly Net Income VS EBIT VS OCF VS FCFPGNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • With an excellent Return On Assets value of 7.11%, PGNY belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
  • PGNY has a Return On Equity of 10.10%. This is in the better half of the industry: PGNY outperforms 71.57% of its industry peers.
  • The Return On Invested Capital of PGNY (11.24%) is better than 83.33% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PGNY is in line with the industry average of 9.16%.
  • The last Return On Invested Capital (11.24%) for PGNY is above the 3 year average (8.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.11%
ROE 10.1%
ROIC 11.24%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
PGNY Yearly ROA, ROE, ROICPGNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • The Profit Margin of PGNY (4.46%) is better than 77.45% of its industry peers.
  • PGNY's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 6.77%, PGNY is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PGNY has grown nicely.
  • PGNY has a Gross Margin (22.94%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of PGNY has grown nicely.
Industry RankSector Rank
OM 6.77%
PM (TTM) 4.46%
GM 22.94%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
PGNY Yearly Profit, Operating, Gross MarginsPGNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
  • The number of shares outstanding for PGNY has been reduced compared to 1 year ago.
  • PGNY has more shares outstanding than it did 5 years ago.
  • PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PGNY Yearly Shares OutstandingPGNY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PGNY Yearly Total Debt VS Total AssetsPGNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • PGNY has an Altman-Z score of 7.91. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.91, PGNY belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
  • There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.91
ROIC/WACC1.26
WACC8.92%
PGNY Yearly LT Debt VS Equity VS FCFPGNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that PGNY has no problem at all paying its short term obligations.
  • PGNY has a Current ratio of 2.96. This is amongst the best in the industry. PGNY outperforms 83.33% of its industry peers.
  • PGNY has a Quick Ratio of 2.96. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.96, PGNY belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
PGNY Yearly Current Assets VS Current LiabilitesPGNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • PGNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.62%, which is quite good.
  • The Earnings Per Share has been decreasing by -4.77% on average over the past years.
  • PGNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.41%.
  • The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.62%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)11.41%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.32%

3.2 Future

  • Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 32.94% on average per year.
  • PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.83% yearly.
EPS Next Y17.75%
EPS Next 2Y29.28%
EPS Next 3Y26.74%
EPS Next 5Y32.94%
Revenue Next Year11.37%
Revenue Next 2Y10.44%
Revenue Next 3Y10.6%
Revenue Next 5Y8.83%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PGNY Yearly Revenue VS EstimatesPGNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
PGNY Yearly EPS VS EstimatesPGNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 36.14, which means the current valuation is very expensive for PGNY.
  • Compared to the rest of the industry, the Price/Earnings ratio of PGNY is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 28.25, PGNY is valued a bit more expensive.
  • With a Price/Forward Earnings ratio of 23.90, PGNY is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PGNY is on the same level as its industry peers.
  • PGNY is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 36.14
Fwd PE 23.9
PGNY Price Earnings VS Forward Price EarningsPGNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PGNY is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, PGNY is valued cheaper than 84.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.15
EV/EBITDA 15.58
PGNY Per share dataPGNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • PGNY has a very decent profitability rating, which may justify a higher PE ratio.
  • PGNY's earnings are expected to grow with 26.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.04
PEG (5Y)N/A
EPS Next 2Y29.28%
EPS Next 3Y26.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PGNY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROGYNY INC

NASDAQ:PGNY (2/4/2026, 8:00:01 PM)

After market: 22.51 -0.26 (-1.14%)

22.77

-0.47 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners104.67%
Inst Owner Change-0.96%
Ins Owners1.48%
Ins Owner Change0.5%
Market Cap1.96B
Revenue(TTM)1.27B
Net Income(TTM)56.57M
Analysts81.18
Price Target30.8 (35.27%)
Short Float %4.61%
Short Ratio2.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.43%
Min EPS beat(2)14.22%
Max EPS beat(2)14.63%
EPS beat(4)3
Avg EPS beat(4)8.02%
Min EPS beat(4)-11.77%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)7.07%
EPS beat(12)9
Avg EPS beat(12)35.08%
EPS beat(16)13
Avg EPS beat(16)94.29%
Revenue beat(2)2
Avg Revenue beat(2)2.31%
Min Revenue beat(2)1.96%
Max Revenue beat(2)2.66%
Revenue beat(4)4
Avg Revenue beat(4)3.39%
Min Revenue beat(4)1.96%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.43%
Revenue beat(12)7
Avg Revenue beat(12)0.39%
Revenue beat(16)9
Avg Revenue beat(16)-0.09%
PT rev (1m)3.78%
PT rev (3m)5.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.45%
EPS NY rev (1m)0%
EPS NY rev (3m)6.34%
Revenue NQ rev (1m)0.47%
Revenue NQ rev (3m)1.61%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)1.48%
Valuation
Industry RankSector Rank
PE 36.14
Fwd PE 23.9
P/S 1.55
P/FCF 10.15
P/OCF 9.43
P/B 3.51
P/tB 3.68
EV/EBITDA 15.58
EPS(TTM)0.63
EY2.77%
EPS(NY)0.95
Fwd EY4.18%
FCF(TTM)2.24
FCFY9.86%
OCF(TTM)2.41
OCFY10.6%
SpS14.72
BVpS6.5
TBVpS6.19
PEG (NY)2.04
PEG (5Y)N/A
Graham Number9.6
Profitability
Industry RankSector Rank
ROA 7.11%
ROE 10.1%
ROCE 14.68%
ROIC 11.24%
ROICexc 27.43%
ROICexgc 30.82%
OM 6.77%
PM (TTM) 4.46%
GM 22.94%
FCFM 15.25%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexgc growth 3Y11.16%
ROICexgc growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 330.21%
Cap/Sales 1.16%
Interest Coverage 250
Cash Conversion 230.54%
Profit Quality 342.01%
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z 7.91
F-Score7
WACC8.92%
ROIC/WACC1.26
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y17.75%
EPS Next 2Y29.28%
EPS Next 3Y26.74%
EPS Next 5Y32.94%
Revenue 1Y (TTM)11.41%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.32%
Revenue Next Year11.37%
Revenue Next 2Y10.44%
Revenue Next 3Y10.6%
Revenue Next 5Y8.83%
EBIT growth 1Y31.12%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year40.11%
EBIT Next 3Y20.4%
EBIT Next 5Y15.66%
FCF growth 1Y-2.78%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y2.69%
OCF growth 3Y90.18%
OCF growth 5YN/A

PROGYNY INC / PGNY FAQ

What is the fundamental rating for PGNY stock?

ChartMill assigns a fundamental rating of 7 / 10 to PGNY.


Can you provide the valuation status for PROGYNY INC?

ChartMill assigns a valuation rating of 4 / 10 to PROGYNY INC (PGNY). This can be considered as Fairly Valued.


How profitable is PROGYNY INC (PGNY) stock?

PROGYNY INC (PGNY) has a profitability rating of 7 / 10.


What is the earnings growth outlook for PROGYNY INC?

The Earnings per Share (EPS) of PROGYNY INC (PGNY) is expected to grow by 17.75% in the next year.